亚辉龙公告称，根据深圳市工业和信息化局公示，公司成功入选第九批国家级制造业单项冠军企业，入 选产品为"自身免疫疾病诊断产品"。这是对公司产品技术和质量的认可，体现了公司综合实力，利于加 强品牌影响力和市场竞争力，对经营有积极影响，但不会对当期业绩产生重大影响。 ...

格隆汇11月5日丨亚辉龙(688575.SH)公布，根据深圳市工业和信息化局近日发布的《关于第九批制造业 单项冠军企业和复核通过第三批、第六批制造业单项冠军企业名单的公示》，公司成功入选第九批国家 级制造业单项冠军企业，入选产品为公司的"自身免疫疾病诊断产品"。 ...

智通财经APP讯，亚辉龙(688575.SH)发布公告，根据深圳市工业和信息化局近日发布的《关于第九批 制造业单项冠军企业和复核通过第三批、第六批制造业单项冠军企业名单的公示》，公司成功入选第九 批国家级制造业单项冠军企业，入选产品为公司的"自身免疫疾病诊断产品"。 公司本次成功入选第九批国家级制造业单项冠军企业，是对公司产品技术、产品质量的认可及肯定，是 公司行业地位、自主创新能力等综合实力的体现，有利于加强公司产品的品牌影响力及市场竞争力，对 公司经营将产生积极影响。 ...

智通财经APP讯，亚辉龙(688575.SH)发布公告，根据深圳市工业和信息化局近日发布的《关于第九批 制造业单项冠军企业和复核通过第三批、第六批制造业单项冠军企业名单的公示》，公司成功入选第九 批国家级制造业单项冠军企业，入选产品为公司的"自身免疫疾病诊断产品"。 公司本次成功入选第九批国家级制造业单项冠军企业，是对公司产品技术、产品质量的认可及肯定，是 公司行业地位、自主创新能力等综合实力的体现，有利于加强公司产品的品牌影响力及市场竞争力，对 公司经营将产生积极影响。 ...

点评： 1. 国内业绩环比回升，海外增速持续亮眼。25Q1-3，受行业政策和国内需求短期承压影响，公司自产 主营业务营收10.74 亿元（同比-5.9%），其中自产发光营收9.67 亿元（同比-6.7%），海外业务持续高 增长，自产主营业务营收2.08 亿元（同比+39%），其中发光营收1.9 亿元（同比+42%）。随着国内发 光检测需求的持续回暖，25Q3 业绩实现拐点向上，整体自产主营业务营收4.03 亿元（同比+14.4%）， 其中自产发光营收3.64 亿元（同比+14%），分区域看，国内自产主营业务营收3.24 亿元（同比+6%， 环比+27.7%）、自产发光营收2.9 亿元（同比+4.6%，环比+29%），海外自产主营业务营收0.79 亿元 （同比+68.5%，环比+9.8%）、自产发光营收0.74 亿元（同比+75.6%，环比+16.2%，其中发光试剂收 入同比增长超50%）。 2. 发光仪+流水线加速装机，特色管线持续落地。25Q1-3，公司自产发光仪新增装机1806 台，其中国内 新增963 台（600 速机占比44.55%），海外新增843 台（同比+15.16%，其中300 速机同比+73 ...

证券之星消息，根据市场公开信息及11月4日披露的机构调研信息，广发基金近期对4家上市公司进行了调研，相关名单如下： 1）亚辉龙 （广发基金参与公司业绩说明会&券商电话会） 调研纪要：2025年第三季度，公司实现营业收入3亿元、归母净利润1.14亿元，剔除政府补贴及其他投资收益影响后净利润同比增长60%。国内前 三季度销量增速保持在20%以上，受集采影响收入基本持平。毛利率环比提升，主因生产效率提高与成本优化，预计全年毛利率恢复至70%以 上。海外收入同比增速超65%，占比提升至18%。Hector?计划11月开展国内多中心临床植入，已在欧洲获定制许可并启动销售。Cratos?覆盖约50 家临床中心，反馈良好。海外多款产品加速放量，国际业务毛利率提升至50%以上。 4）中联重科 （广发基金参与公司业绩说明会&线上） 个股亮点：公司拥有一个国家A级、国际T3+级的超算中心，现有GPU算力59P，支持1000个机柜，1万个服务器和混合云算力弹性扩展。；公司的 隧道掘进机械等设备可用于水利项目建设；中联重科作为全球领先的高端装备制造企业，与项目相关的承建方多年来有长期战略合作伙伴关系， 有望深度参与项目建设的核心环节 ...

Summary of the Conference Call for 亚辉龙 (Aihuilong) Company Overview - **Company**: 亚辉龙 (Aihuilong) - **Industry**: In Vitro Diagnostics (IVD) Key Financial Performance - **Revenue**: - Total revenue for the first three quarters of 2025 was 1.287 billion yuan, a year-on-year decline of 7.69% [3] - Main business revenue was 1.257 billion yuan, down 7.8% year-on-year [3] - Revenue for Q3 2025 was 478 million yuan, showing a year-on-year growth of 10.25% and a quarter-on-quarter increase of 22.44% [5] - **Gross Margin**: - Main business gross margin was 60.85%, down 2.5 percentage points year-on-year [6] - Self-operated business gross margin was 67.42%, down 3.08 percentage points year-on-year [6] Market Performance - **Domestic vs. International Revenue**: - Domestic self-operated business revenue was 866 million yuan, down 12.74% year-on-year, accounting for 80.63% of total self-operated revenue [3] - International self-operated business revenue was 208 million yuan, up 39.39% year-on-year, accounting for 19.37% of total self-operated revenue [3] Business Segments - **Chemiluminescence Business**: - Revenue for the first three quarters was 967 million yuan, down 6.66% year-on-year [7] - Q3 revenue was 364 million yuan, up 13.99% year-on-year and 26.16% quarter-on-quarter [8] - Domestic chemiluminescence revenue was 777 million yuan, down 13.89% year-on-year, while international revenue was 190 million yuan, up 41.96% [7] Installation and Market Expansion - **Instrument Installation**: - As of September 30, 2025, over 12,410 self-operated chemiluminescence instruments were installed, with 1,806 new installations in the first three quarters [9] - Domestic installations accounted for 44.55% of new installations, while international installations grew by 15.16% [9] - **Market Coverage**: - Products covered over 6,200 medical institutions in China, with a 70% coverage rate in top-tier hospitals [10] Research and Development - **Innovation**: - Collaborated with the National University of Singapore on cardiovascular research, leading to the commercialization of a patented test kit [4] - The ANA intelligent interpretation system has achieved a 95% accuracy rate, with a target of 98% [12] - The pancreatic function platform is expected to be approved in 2026, with a business model that includes direct software sales and clinical education [13][14] Industry Dynamics - **Market Trends**: - The IVD industry is undergoing structural changes, with domestic brands gaining market share against imports [16][17] - The number of IVD companies has significantly decreased, with expectations of a market recovery in 2026 [25][24] - **Policy Impact**: - The implementation of centralized procurement policies has positively impacted the company's market share and testing volume [26][24] Future Outlook - **Strategic Plans**: - Focus on enhancing existing specialty projects and expanding market share [18] - Plans to enter the Japanese market with 12 projects submitted for approval, expecting significant revenue contributions starting in 2027 [31] - Continued investment in AI and IVD applications to enhance technological capabilities and market competitiveness [15] Conclusion - **Long-term Vision**: The company aims to become a leading player in the domestic IVD market within five years and a global leader in specific diagnostic fields within ten years [34]

Core Viewpoint - The company reported a decline in revenue and net profit for the first three quarters of 2025, primarily due to industry policy impacts and reduced domestic market demand [1] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 1.287 billion yuan, a year-on-year decrease of 7.69% [1] - The net profit attributable to shareholders was 60.42 million yuan, down 72.36% year-on-year [1] - In the third quarter, the company recorded revenue of 478 million yuan, an increase of 10.25% compared to the same period last year [1] - The net profit attributable to shareholders in the third quarter was 34.15 million yuan, a decrease of 25.12% year-on-year [1] Factors Affecting Performance - The decline in performance for the first three quarters was attributed to reduced domestic market demand and losses from the fair value changes of trading financial assets, specifically shares in Cloud Health Group Limited [1]

Core Insights - The company, Aihuilong (688575.SH), reported a total operating revenue of 1.287 billion yuan for the first three quarters of 2025, representing a year-on-year decrease of 7.69% [1] - The net profit attributable to shareholders of the parent company was 60.42 million yuan, down 72.36% year-on-year [1] - The basic earnings per share stood at 0.11 yuan [1]

Core Insights - The company reported a revenue of 1.287 billion yuan and a net profit attributable to shareholders of 60.42 million yuan for the first three quarters of 2025, with a non-deducted net profit of 101 million yuan [2] - Research and development expenses amounted to 209 million yuan, representing 16.23% of total revenue [2] - The company's international expansion has shown significant results, with overseas markets becoming a new growth point for revenue [2] Revenue Breakdown - The overseas self-produced main business generated revenue of 208 million yuan, a year-on-year increase of 39.39%, accounting for 16.16% of total revenue [2] - Revenue from overseas chemiluminescence business reached 190 million yuan, up 41.96% year-on-year [2] - Revenue from overseas chemiluminescence reagents (including consumables) was 117 million yuan, reflecting a year-on-year growth of 50.79% [2] Quarterly Performance - From July to September, the overseas self-produced main business achieved revenue of 79.17 million yuan, a year-on-year increase of 68.53%, and a quarter-on-quarter growth of 9.78% [2] - Revenue from overseas chemiluminescence business during the same period was 74.24 million yuan, showing a year-on-year increase of 75.64% and a quarter-on-quarter growth of 16.24% [2] - Revenue from overseas self-produced chemiluminescence reagents (including consumables) was 43 million yuan, with a year-on-year growth of 52.41% [2] International Market Coverage - The company actively expands its international market, covering 120 countries and regions across the Americas, Europe, Asia, and Africa [3]